Recruiting PHASE1 INTERVENTIONAL 1-arm NCT06256055

Phase 1 Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

A First-In-Human, Single Arm, Open-label, Phase 1 Dose-Escalation Study of UCMYM802 Injection in Mesothelin-positive Advanced Malignant Solid Tumors

Sponsor: Peking University Cancer Hospital & Institute

Conditions Bile Duct Cancer Breast Cancer Female Colorectal Cancer Malignant Mesothelioma Ovary Cancer Pancreatic Cancer Rectal Cancer

Interventions UCMYM802 Injection

Updated 5 times since 2024 Last updated: Jul 22, 2024 Started: Mar 5, 2024 Primary completion: Mar 31, 2025 Completion: Apr 30, 2025

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06256055, this PHASE1 trial focuses on Bile Duct Cancer and Breast Cancer Female and remains actively recruiting participants. Sponsored by Peking University Cancer Hospital & Institute, it has been updated 5 times since 2024, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Recruiting PHASE1
Aug 2024 — Sep 2024 [monthly]

Recruiting PHASE1
Jul 2024 — Aug 2024 [monthly]

Recruiting PHASE1
Apr 2024 — Jul 2024 [monthly]

Recruiting PHASE1
Mar 2024 — Apr 2024 [monthly]

Recruiting PHASE1

First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Peking University Cancer Hospital & Institute
UTC Therapeutics Inc.

Data source: UTC Therapeutics Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Beijing, China